Desert Daily

Propulsion of Liver Cancer Clinical Trial Pipeline as Novel and Extensive 75+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Liver Cancer Clinical Trial Pipeline as Novel and Extensive 75+ Therapies Likely to Enter in the Domain | DelveInsight

August 28
21:55 2023
Propulsion of Liver Cancer Clinical Trial Pipeline as Novel and Extensive 75+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Liver Cancer Pipeline constitutes 75+ key companies continuously working towards developing 75+ Liver Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Liver Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Liver Cancer NDA approvals (if any), and product development activities comprising the technology, Liver Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Liver Cancer Pipeline treatment landscape of the report, click here @ Liver Cancer Pipeline Outlook

 

Key Takeaways from the Liver Cancer Pipeline Report

  • DelveInsight’s Liver Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
  • The leading companies working in the Liver Cancer market include Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others.
  • Promising Liver Cancer Pipeline Therapies in the various stages of development include Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.
  • On May 2023, Binhui Biopharma Co Ltd announced a study of phase 1 clinical trials for OH2 Injection. An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma.
  • On August 2023, Hoffmann-La Roche announced a study of phase 1 & 2 clinical trials for This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.

 

Liver Cancer Overview

Liver cancer is a cancer that originates in the liver, and is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Primary liver cancer, or hepatocellular carcinoma (HCC), is the fifth most common cancer in males and the seventh most common cancer in females, and is the third leading cause of cancer-related death worldwide.

 

For further information, refer to the detailed Liver Cancer Unmet Needs, click here for Liver Cancer Ongoing Clinical Trial Analysis

 

Liver Cancer Emerging Drugs Profile

  • SRF388: Surface Oncology
  • MTL-CEBPA: MiNA Therapeutics
  • APX3330: Ocuphire Pharma
  • Fostroxacitabine bralpamide: Medivir
  • CDX-527: Celldex Therapeutics

 

Liver Cancer Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies Liver Cancer. The Liver Cancer companies which have their Liver Cancer drug candidates in the most advanced stage, i.e. phase III include, Polaris Group.

 

Request a sample and discover the recent advances in Liver Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Liver Cancer Segmentation

 

Liver Cancer Drugs and Companies

  • Atezolizumab: Hoffmann- La Roche
  • Bevacizumab: Adagene Inc.
  • Tiragolumab: Tempest Therapeutics
  • OMP-54F28 with Sorafenib: OncoMed Pharmaceuticals Inc.

 

Liver Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Liver Cancer Therapeutics Market include-

Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others.

 

Dive deep into rich insights for drugs for the Liver Cancer Pipeline, Click here @ Liver Cancer Unmet Needs and Analyst Views

 

Scope of the Liver Cancer Pipeline Report

  • Coverage- Global
  • Companies- Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, MiNA Therapeutics, Abbisko Therapeutics, Medivir AB, Teclison, Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, and others.
  • Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Liver Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Liver Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Liver Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ADI-PEG20: Polaris Group
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Brivanib alaninate: ZAI Lab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ABSK 011: Abbisko Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Liver Cancer Key Companies
  21. Liver Cancer Key Products
  22. Liver Cancer- Unmet Needs
  23. Liver Cancer- Market Drivers and Barriers
  24. Liver Cancer- Future Perspectives and Conclusion
  25. Liver Cancer Analyst Views
  26. Liver Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories